United Therapeutics Corp (FRA:UTH)
€ 245.3 4.6 (1.91%) Market Cap: 10.88 Bil Enterprise Value: 8.92 Bil PE Ratio: 12.50 PB Ratio: 2.19 GF Score: 89/100

United Therapeutics Corp at Goldman Sachs Global Healthcare Conference Transcript

Jun 11, 2019 / 08:20PM GMT
Release Date Price: €72.88 (+1.87%)
Terence C. Flynn
Goldman Sachs Group Inc., Research Division - MD

Okay. Great. Well, thanks, everyone, for joining us for the afternoon session, really appreciate it. I'm Terence Flynn, one of the biotech analysts here at Goldman. We're very pleased to welcome United Therapeutics.

Joining us from -- today from the company, we have James Edgemond, CFO. James, thank you very much for being here, really appreciate you taking the time.

James C. Edgemond
United Therapeutics Corporation - CFO & Treasurer

Great. Terence, thank you for the invitation to the conference. We've had really good meetings this morning, and I'm looking forward to continuing the conversation with you right here.

Questions & Answers

Terence C. Flynn
Goldman Sachs Group Inc., Research Division - MD

Great. Absolutely. Maybe just to get started, you could just give us an overview of your current PAH portfolio and maybe help us think about the forward growth drivers here for your marketed drugs as we think through kind of the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot